Evogene Ltd. logo
Evogene Ltd. EVGN
$ 1.06 2.91%

Annual report 2024
added 11-29-2025

report update icon

Evogene Ltd. Balance Sheet 2011-2025 | EVGN

Annual Balance Sheet Evogene Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - - -3.44 M -3.24 M -10.2 M -5.21 M -95.5 M -24.3 M -

Long Term Debt Current

589 K 853 K 884 K 974 K 777 K 895 K - - - - - - - -

Total Non Current Liabilities

- - - - 5.36 M 5.42 M 2.96 M 3.56 M 3.47 M 3.2 M 3.58 M 3.99 M 7.1 M -

Total Liabilities

- - - - 15 M 11.1 M 8.39 M 8.22 M 8.7 M 8.84 M 11.5 M 12.6 M 16.6 M -

Deferred Revenue

- - - - 119 K 386 K 412 K 516 K 967 K 560 K 1.51 M 1.57 M 4.94 M -

Retained Earnings

- - - - -179 M -156 M -138 M -117 M -96.2 M -76.6 M -59.4 M -44.9 M -36 M -

Total Assets

39.9 M 51.1 M 56.1 M 76.3 M 71.9 M 71.4 M 58.7 M 77.6 M 96 M 113 M 128 M 137 M 64.9 M -

Cash and Cash Equivalents

15.3 M 20.8 M 29 M 32.3 M 46.2 M 34.7 M 5.81 M 3.44 M 3.24 M 10.2 M - - - -

Book Value

39.9 M 51.1 M 56.1 M 76.3 M 56.9 M 60.2 M 50.3 M 69.4 M 87.3 M 104 M 116 M 125 M 48.3 M -

Total Shareholders Equity

- - - - 56.9 M 60.2 M 50.3 M 69.4 M 87.3 M - - - - -

All numbers in USD currency

Quarterly Balance Sheet Evogene Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 1.7 M - 1.6 M - 1.66 M - 1.79 M - 2.08 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 6 M - 5.57 M - 5.36 M - 5.31 M - 5.4 M - - - 2.96 M - - - 3.56 M - - - 3.47 M - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -207 M - -192 M - -179 M - -166 M - -156 M - - - -138 M - - - -117 M - - - -96.2 M - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 76.3 M - 87.5 M - 71.9 M - 61.1 M - 71.4 M - - - 58.7 M - - - 77.6 M - - - 96 M - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 32.3 M - 42.8 M - 46.2 M - 31.1 M - 34.7 M - 14.1 M - 5.81 M - - - 3.44 M - - - 3.24 M - - - 10.2 M - - - 5.21 M - - - - - - - - - - - - - - -

Book Value

- - - - 76.3 M - 87.5 M - 71.9 M - 61.1 M - 71.4 M - - - 58.7 M - - - 77.6 M - - - 96 M - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 63.4 M - 76.6 M - 56.9 M - 51 M - 60.2 M - 42.9 M - 50.3 M - - - 69.4 M - - - 87.3 M - - - 104 M - - - 116 M - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Evogene Ltd., providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
AC Immune SA AC Immune SA
ACIU
$ 2.8 2.19 % $ 229 M schweizSchweiz
ADiTx Therapeutics ADiTx Therapeutics
ADTX
$ 2.49 -11.39 % $ 32.8 K usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 4.59 -4.08 % $ 98.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 12.12 -1.58 % $ 3.74 B usaUSA
Axcella Health Axcella Health
AXLA
- -16.42 % $ 249 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 5.37 -20.68 % $ 194 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
argenx SE argenx SE
ARGX
$ 919.62 2.76 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 203.0 -3.72 % $ 5 B danmarkDanmark
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 4.64 -0.32 % $ 92 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.36 2.73 % $ 8.08 B australiaAustralia
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
BioLineRx Ltd. BioLineRx Ltd.
BLRX
$ 3.29 -1.5 % $ 908 M israelIsrael
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.27 -1.38 % $ 10.3 B usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
AbbVie AbbVie
ABBV
$ 224.99 -0.01 % $ 398 B usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 96.22 -1.21 % $ 27.2 B germanyGermany
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 18.75 -0.48 % $ 2.76 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.92 -7.01 % $ 4.87 M usaUSA
Biogen Biogen
BIIB
$ 179.76 1.11 % $ 26.2 B usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Beam Therapeutics Beam Therapeutics
BEAM
$ 23.52 -2.22 % $ 1.94 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.45 -0.72 % $ 1.02 B canadaCanada
Cabaletta Bio Cabaletta Bio
CABA
$ 2.37 -2.67 % $ 2.77 M usaUSA
Clearside Biomedical Clearside Biomedical
CLSD
- - $ 25.3 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA